Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Myasthenia gravis (MG) is an autoimmune disease that presents with fatigable muscle weakness caused by the autoantibodies mostly to acetylcholine receptor (AChR). Around 10-15% of MG patients have thymoma, which contributes to the dysregulation of negative selection and permits the production of autoantibodies to soluble cytokines, e.g., type I interferons, IL-12/IL-23 etc. Those autoantibodies can neutralize their targets and disrupt their normal functions in patients. To detect them, HEK293T cells were transfected with the DNA constructs for expressing the targeted cytokines above cell membrane. This was to provide the native substrates for antibody binding and to detect cytokine autoantibodies more sensitively. Moreover, myc tag was incorporated for our benefit to quantify the surface expression of targeted cytokines. Our platform was able to prognose the presence of thymoma in a series of thymoma-related autoimmune disorders, e.g. thymoma-associated MG (TAMG), late-onset MG (LOMG), neuromyotonia (NMT) and Good’s syndrome. In general, we have established a live cell-based assay to optimize the detection of cytokine autoantibodies in the sera from patients with thymoma for gaining proof of concept and beneficial clinical interpretations. The poster was presented at International Thymic Malignancy Interest Group (ITMIG) 2019 Annual Conference.



Publication Date